BeiGene announces clinical results of anti-PD-1 antibody- Tislelizumab
Category: #health  By Mateen Dalal  Date: 2019-09-23
  • share
  • Twitter
  • Facebook
  • LinkedIn

BeiGene announces clinical results of anti-PD-1 antibody- Tislelizumab

With novel clinical trials, organizations across the world are developing new therapies and next-generation treatment for targeting fatal diseases such as cancer. The result of such clinical trials can aid the improvement in existing treatments and give patients hope for a better future.

BeiGene Ltd. is one such commercial-stage biopharmaceutical company that develops and commercializes immuno-oncology drugs and innovative molecularly-targeted for cancer treatment. Recently, the firm has announced its clinical results on investigational anti-PD-1 antibody Tislelizumab from 3 ongoing trials in China.

Reportedly, these results were presented at 22nd Annual Meeting of CSCO (Chinese Society of Clinical Oncology) held in Xiamen, China. Apart from this, the company also presented additional four poster presentations on pamiparib, tislelizumab, and zanubrutinib.

According to Yong (Ben) Ben, Chief Medical Officer, M.D., Immuno-Oncology at BeiGene, said that the data shows the potential of tislelizumab to benefit patients in cancer treatment, specially to fulfill an unmet need in China and around the world.

He said that, in anticipation of the company’s first regulatory approvals in China for tislelizumab in urothelial carcinoma and Hodgkin’s lymphoma, their firm is approaching the 1st stage completion on the cutting-edge biologics manufacturing facility, which will be a model for quality biologics manufacturing operations.

Incidentally, the company’s announced results of the Phase 2 trial of tislelizumab were also in combination with chemotherapy as first-line treatment for an advanced lung cancer patient in China.

About BeiGene

BeiGene is a research-based, commercial-stage, commercial-stage biotechnology focusing on immuno-oncology and molecularly targeted cancer therapeutics. The company is working to create combination solutions that aim to have both lasting and meaningful impact on cancer treatment.

With a team around 2,700 employees in China, Australia, Europe, and the United States, the company is working towards developing novel oral small molecules and monoclonal antibodies for treating cancer.

Some drugs that BeiGene markets include REVLIMID® (lenalidomide), ABRAXANE® (nanoparticle albumin-bound paclitaxel), and VIDAZA® (azacitidine) under a license from Celgene Corporation in China.

 Source Credit -https://www.globenewswire.com/news-release/2019/09/22/1918784/0/en/BeiGene-Announces-Clinical-Results-on-Tislelizumab-Presented-at-the-22nd-Annual-Meeting-of-the-Chinese-Society-of-Clinical-Oncology-CSCO.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Alphabet’s Google to face lawsuit from NLRB for violating labor laws
Alphabet’s Google to face lawsuit from NLRB for violating labor laws
By Mateen Dalal

In a recent turn of events, U.S. government body National Labor Relations Board (NLRB) has reportedly issued a complaint against American multinational technology company, Google LLC for unlawfully monitoring as well as questioning its workers and su...

Britain’s CMA to levy tougher competition rules on Google and Facebook
Britain’s CMA to levy tougher competition rules on Google and Facebook
By Mateen Dalal

Facebook and Google accounted for around 80% of the total 14 billion pounds spent on digital advertising in 2019. MOW has reportedly accused Google of modifying its Chromium developer tools and Chrome browser to get greater control over advertiser...

Amazon, U.S. Government team up to prevent sale of counterfeit goods
Amazon, U.S. Government team up to prevent sale of counterfeit goods
By Mateen Dalal

According to reliable sources, Washington-headquartered American multinational technology company, Amazon.com Inc has reportedly initiated a joint venture with the U.S. government’s counterfeit agency, the IPR Center (National Intellectual Prop...